PMID- 20712008
OWN - NLM
STAT- MEDLINE
DCOM- 20101207
LR  - 20220310
IS  - 1699-5848 (Electronic)
IS  - 0213-3911 (Linking)
VI  - 25
IP  - 10
DP  - 2010 Oct
TI  - Angiogenesis index CD105 (endoglin)/CD31 (PECAM-1) as a predictive factor for 
      invasion and proliferation in intraductal papillary mucinous neoplasm (IPMN) of 
      the pancreas.
PG  - 1239-46
LID - 10.14670/HH-25.1239 [doi]
AB  - BACKGROUND: Intraductal papillary-mucinous neoplasm (IPMN) of the pancreas is an 
      increasingly diagnosed entity since its definition by the World Health 
      Organization in 1996. It has a broad clinical spectrum ranging from benign to 
      malignant tumors. Optimum treatment is controversial and a better understanding 
      of the development of IPMN of the pancreas and identification of potential 
      prognostic factors will help to address this. Angiogenesis plays an elementary 
      role in the development of malignant tumors and may well also be important in the 
      development of IPMN of the pancreas. Therefore we investigated endothelial cell 
      marker CD31 (PECAM-1) and angiogenesis associated marker CD105 (endoglin) by 
      immunohistochemistry. METHODS: Thirty-two cases of surgically resected IPMN were 
      chosen retrospectively and clinical data were obtained. Specimens were stained 
      for proliferation marker (Ki-67), CD31 and CD105 by immunohistochemistry. A 
      CD105/CD31 Angiogenesis ratio (AR) was established to determine the proliferating 
      fraction of endothelial cells. RESULTS: The AR is significantly elevated in 
      invasive IPMN of the pancreas (Mann-Whitney-U Test, p<0.05) and is associated 
      with the Ki-67-labelling-index, demonstrating synergy between tumor-growth and 
      neovascularisation. Invasive IPMN of the pancreas is associated with 
      significantly lower recurrence-free and overall survival. CONCLUSIONS: 
      Neovascularisation plays an important role in the tumorigenesis of invasive IPMN 
      of the pancreas, and therefore angiogenesis-associated molecules like CD105 and 
      CD31 might be useful tools as prognostic markers. Furthermore, the results 
      indicate a potential role for adjuvant anti-angiogenic therapies in selected 
      patients with recurring and/or invasive IPMN of the pancreas.
FAU - Tachezy, Michael
AU  - Tachezy M
AD  - Department of General-, Visceral-, and Thoracic-Surgery, University Medical 
      Center Hamburg Eppendorf, Germany. mtachezy@uke.uni-hamburg.de
FAU - Reichelt, Uta
AU  - Reichelt U
FAU - Melenberg, Tanja
AU  - Melenberg T
FAU - Gebauer, Florian
AU  - Gebauer F
FAU - Izbicki, Jakob R
AU  - Izbicki JR
FAU - Kaifi, Jussuf T
AU  - Kaifi JT
LA  - eng
PT  - Journal Article
PL  - Spain
TA  - Histol Histopathol
JT  - Histology and histopathology
JID - 8609357
RN  - 0 (Antigens, CD)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (ENG protein, human)
RN  - 0 (Endoglin)
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Platelet Endothelial Cell Adhesion Molecule-1)
RN  - 0 (Receptors, Cell Surface)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antigens, CD/*analysis
MH  - Biomarkers, Tumor/*analysis
MH  - Carcinoma, Pancreatic Ductal/blood supply/*chemistry/mortality/pathology
MH  - Carcinoma, Papillary/blood supply/*chemistry/mortality/pathology
MH  - *Cell Proliferation
MH  - Endoglin
MH  - Female
MH  - Germany
MH  - Humans
MH  - Immunohistochemistry
MH  - Kaplan-Meier Estimate
MH  - Ki-67 Antigen/analysis
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Staging
MH  - Neoplasms, Cystic, Mucinous, and Serous/blood 
      supply/*chemistry/mortality/pathology
MH  - Neovascularization, Pathologic/*metabolism/pathology
MH  - Pancreatic Neoplasms/blood supply/*chemistry/mortality/pathology
MH  - Platelet Endothelial Cell Adhesion Molecule-1/*analysis
MH  - Prognosis
MH  - Receptors, Cell Surface/*analysis
MH  - Retrospective Studies
MH  - Time Factors
EDAT- 2010/08/17 06:00
MHDA- 2010/12/14 06:00
CRDT- 2010/08/17 06:00
PHST- 2010/08/17 06:00 [entrez]
PHST- 2010/08/17 06:00 [pubmed]
PHST- 2010/12/14 06:00 [medline]
AID - 10.14670/HH-25.1239 [doi]
PST - ppublish
SO  - Histol Histopathol. 2010 Oct;25(10):1239-46. doi: 10.14670/HH-25.1239.